The purchase will be announced early next week in conjunction with the United Nations General Assembly meeting in New York.
The United States plans to purchase hundreds of millions of additional doses of the Covid-19 vaccine from Pfizer Inc. To donate worldwide. This was reported by the Washington Post, citing two unidentified persons familiar with the agreement.
The sources, who requested anonymity, said that the purchase will be announced early next week in conjunction with the meeting of the United Nations General Assembly in New York.
President Joe Biden has stressed the importance of a global vaccination campaign as a way to defeat the virus. The United States planned to hold a virtual summit on COVID-19 on the sidelines of the General Assembly meeting.
The United States is pressing world leaders to support its goals to end the COVID-19 pandemic, including ensuring that 70% of the world’s population is vaccinated by 2022, according to a draft US document seen by Reuters.
The newspaper stated that the details of the deal were not final.
The White House and Pfizer could not be reached for comment.
The study found that the Moderna vaccine produces twice as many antibodies as Pfizer
Those immunized with the Moderna vaccine had twice as many antibodies as those receiving the injections from Pfizer and BioNTech, according to a peer-reviewed study published Monday in the Journal of the American Medical Association (JAMA).
“This study demonstrated a significantly higher humoral immune capacity for the (modern) SARS-CoV-2 mRNA-1273 vaccine compared to the BNT162b2 (Pfizer-BioNTech) vaccine, in both infected and uninfected participants, and in all age groups.”, say the authors of the research.
The results indicate that the amount of active ingredient in dosing and the time interval between the first and second injections can play an important role in differing immune responses.
The Study volunteers They were health care workers from a center in Ziekenhuis Oost-Limburg, Belgium, who were scheduled to be vaccinated with two doses of mRNA-1273 (Moderna) or BNT162-2 (Pfizer and BioNTech). Of the 2,499 toilets, 1,647 participated in this study.
A total of 688 were vaccinated with mRNA-1273 (median age, 43.2 years; 76.7% women; 21.8% previously infected with SARS-CoV-2) and 959 infected with BNT162b2 (median age, 44.7 years; 84.9% women; 13.2% previously infected),” the report describes.
Moderna’s vaccine produced twice as many antibodies as Pfizer, according to this study
Participants underwent serological tests before vaccination and 6 to 10 weeks after the second dose, regardless of whether they were infected (or not) with MERS-CoV.
High antibody values were observed in the participants He was vaccinated with two doses From mRNA -1273 [Moderna] Compared to those vaccinated with BNT162b2 [Pfizer]The authors of the study published in JAMA conclude.
In fact, for the study group that had previously been infected, the researchers also found that those vaccinated with the biotech filter continued to have higher antibody titers than those who received those from Pfizer and BioNTech.
The only two vaccines licensed for emergency use based on mRNA technology require two doses to stimulate a strong immune response. Both are effective and more than 90% effective against specific coronavirus variants, including Delta.
The study indicates that the Moderna vaccine generates more antibodies than the Pfizer vaccine
however, Moderna vaccine contains 100 micrograms of the active ingredient, compared to 30 micrograms of the Pfizer vaccine.
In addition, biotechnology injections are given at an interval of 4 weeks, compared to the three weeks between the two-dose pharmaceutical regimen.
These factors, highlighted by the authors who published in JAMA, could influence the study’s outcome.
Other research, not yet peer-reviewed, shows that Pfizer antibody levels can drop as low as 84% within 6 months. When Moderna’s indices, according to its own data, remain stable between 90% and 93% in the same period.
“Pop culture advocate. Troublemaker. Friendly student. Proud problem solver.”